Sr One Capital Management, L.P. is an investment fund managing more than $195 billion ran by Sasha Keough. There are currently 6 companies in Mr. Keough’s portfolio. The largest investments include Arcellx Inc. and Mineralys Therapeutics, together worth $159 billion.
As of 6th August 2024, Sr One Capital Management, L.P.’s top holding is 3,946,630 shares of Arcellx Inc. currently worth over $142 billion and making up 72.6% of the portfolio value.
In addition, the fund holds 1,794,600 shares of Mineralys Therapeutics worth $17.1 billion.
The third-largest holding is Design Therapeutics Inc worth $15.4 billion and the next is Ars Pharmaceuticals worth $15.2 billion, with 4,012,903 shares owned.
Currently, Sr One Capital Management, L.P.'s portfolio is worth at least $195 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Sr One Capital Management, L.P. office and employees reside in Wayne, Pennsylvania. According to the last 13-F report filed with the SEC, Sasha Keough serves as the General Counsel and CCO at Sr One Capital Management, L.P..
The two most similar investment funds to Sr One Capital Management, L.P. are Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet Ltd and Etf Portfolio Partners. They manage $319 billion and $319 billion respectively.
Sr One Capital Management, L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 0.9% of
the total portfolio value.
The fund focuses on investments in the United States as
16.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $357 million.
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Arcellx Inc. |
No change
3,946,630
|
$141,605,084,000 | 72.57% |
| Mineralys Therapeutics |
No change
1,794,600
|
$17,066,646,000 | 8.75% |
| Design Therapeutics Inc |
No change
6,526,476
|
$15,402,483,000 | 7.89% |
| Ars Pharmaceuticals |
No change
4,012,903
|
$15,168,773,000 | 7.77% |
| Effector Therapeutics Inc |
No change
6,822,114
|
$4,025,047,000 | 2.06% |
| Nkarta, Inc. |
No change
1,333,333
|
$1,853,333,000 | 0.95% |
| No transactions found | |||
| Showing first 500 out of 6 holdings | |||